Bevacizumab-awwb (Mvasi)

OncoLink Team
Last Modified: September 21, 2017

Pronounced: BEV-a-SIZ-oo-mab Awwb

Classification: Biosimilar Monoclonal Antibody

About Bevacizumab-awwb (Mvasi)

Monoclonal antibodies are created in a lab to attach to the targets found on specific types of cancer cells. The antibody “calls” the immune system to attack the cell it is attached to, resulting in the immune system killing the cell. These antibodies can work in different ways, including stimulating the immune system to kill the cell, blocking cell growth or other functions necessary for cell growth. A biosimilar monoclonal antibody means that this medication has been approved by the FDA because it is very similar to an FDA-approved medication (called a reference product, or the medication it is being compared to), and that there are no meaningful differences between the biosimilar product and the reference product.

Bevacizumab-awwb is a biosimilar monoclonal antibody that binds to and inhibits the activity of vascular endothelial growth factor (VEGF). This prevents the VEGF from interacting with its receptor on endothelial cells (lining of blood vessel). This, in turn, inhibits the formation of new blood vessels, which slows down the growth of the particular tissue. In essence, it kills tumors by cutting off their blood supply. 

How to Take Bevacizumab-awwb 

Bevacizumab-awwb is given by intravenous (IV, into a vein) infusion. The treatment is delivered over 90 minutes for the first infusion. If that dose is well tolerated, the second infusion can be administered over 60 minutes. Subsequent doses can be given over 30 minutes if well tolerated. Dosage depends on the person’s size and type of cancer being treated. How often you receive this medication and what other medications you receive will be determined by your care team.  

Possible Side Effects 

There are a number of things you can do to manage the side effects of bevacizumab-awwb. Talk to your care team about these recommendations. They can help you decide what will work best for you. These are some of the most common or important side effects: 

High Blood Pressure 

Patients receiving bevacizumab-awwb can develop high blood pressure. Your blood pressure should be monitored at every clinic visit or every 2-3 weeks. If your blood pressure is elevated, you will be treated with a medication to reduce your pressure. If severe hypertension develops, bevacizumab-awwb should be discontinued immediately. In both cases, your blood pressure should continue to be monitored, even if bevacizumab-awwb is stopped. Signs of hypertension to report to your team include: blurry vision, nosebleed, headache and fatigue. 

Bleeding  

Patients may experience minor bleeding, such as a nosebleed. Serious bleeding has also occurred in patients treated with this medication, including coughing up blood, bleeding into the stomach, vomiting blood, bleeding in the brain (stroke), and vaginal bleeding. People who have had serious bleeding should not take this medication. These events are uncommon, though if they occur, bevacizumab-awwb should be discontinued. While a nosebleed may not seem like much of a concern, you should notify your healthcare team right away if you develop bleeding of any sort. 

Wound Healing  

This medication can lead to slower or incomplete wound healing, such as a surgical wound not healing or staying closed. Therefore, it is recommended that the medication be discontinued 4 weeks prior to any surgery. In addition, any surgical incision should be fully healed prior to starting or restarting the medication. If you have a surgical wound that has not healed or begins to have signs of infection (redness, swelling, warmth), report this to your healthcare team. 

Less common, but important side effects can include: 

  • Infusion Reactions: The infusion can cause a reaction that may lead to chills, fever, low blood pressure, nausea and vomiting. Reactions are most common during the first week of therapy, including the evening after the infusion. Let your nurse know if you are feeling any different during your infusion.  
  • Gastrointestinal Perforation: This medication can cause a tear in the intestinal wall, also called a gastrointestinal perforation. Signs of this can include: new or worsening pain in the abdomen, new abdominal swelling, chills, fever, constipation, nausea or vomiting. If you experience any of these, contact your healthcare provider immediately or go to the emergency room. 
  • Kidney Damage: Kidney damage can occur while receiving bevacizumab-awwb. Your healthcare team will monitor this by periodically checking the amount of protein in your urine. If the protein levels become elevated, you may require further urine tests to evaluate your kidney function. If your kidneys become damaged, you may need to stop receiving this medication. 
  • Blood Clots, Stroke and Heart Attack: Bevacizumab-awwb can increase the risk of blood clots, stroke and heart attack. If you experience symptoms of these problems, you should contact your healthcare provider immediately or go to an emergency room. Symptoms can include: swelling, redness or pain in an extremity, chest pain or pressure, pain in your arm, back, neck or jaw, shortness of breath, numbness or weakness on one side of the body, trouble talking, confusion or mental status changes. 
  • Posterior Reversible Encephalopathy Syndrome  (PRES): In rare cases this medication has caused a neurological disorder called posterior reversible encephalopathy syndrome (PRES), also called reversible posterior leukoencephalopathy (RPLS). Symptoms of PRES/RPLS include headache, seizure, lethargy, confusion, blindness and other visual and neurological disturbances. Report any of these symptoms to your healthcare team immediately. 
  • Fistula: A possible, but rare, side effect is the development of a fistula, which is an abnormal passage between two body parts (for instance, a hole between the lung and esophagus). 
  • Low White Blood Cell Count (Leukopenia or Neutropenia): White blood cells (WBC) are important for fighting infection. While receiving treatment, your WBC count can drop, putting you at a higher risk of getting an infection. You should let your doctor or nurse know right away if you have a fever (temperature greater than 100.4), sore throat or cold, shortness of breath, cough, burning with urination, or a sore that doesn't heal. 

Sexual & Reproductive Concerns 

This drug may affect your reproductive system, resulting in the menstrual cycle or sperm production becoming irregular or stopping permanently. Women may experience menopausal effects including hot flashes and vaginal dryness. In addition, the desire for sex may decrease during treatment. 

Exposure of an unborn child to this medication could cause birth defects, so you should not become pregnant or father a child while on this medication. Effective birth control is necessary during treatment and for at least 6 months after treatment, even if your menstrual cycle stops or you believe you are not producing sperm. You may want to consider sperm banking or egg harvesting if you may wish to have a child in the future. Discuss these options with your oncology team. You should not breastfeed while taking this medication.  

Keywords

Click on any of these terms for more related articles

Frequently Asked Questions


A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Stay informed with the latest information from OncoLink!   Subscribe to OncoLink eNews
View our newsletter archives